Prevalence of osteoporosis and low bone mass in men with prostate cancer: a systematic review and meta-analysis.
Mehdi Ebrahimi, Abdolreza Mohammadi, Sogand Sarmadi et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the prevalence of osteoporosis and low bone mass in 91,913 men with prostate cancer (PCa). The study found a pooled prevalence of osteoporosis at 22.0% and low bone mass at 41.7%. The analysis highlighted significant heterogeneity across studies, influenced by various factors including ADT category and geographic region.
Key findings
- The pooled prevalence of osteoporosis in men with PCa was 22.0% (95% CI: 19.9-24.1).
- The pooled prevalence of low bone mass was 41.7% (95% CI: 36.6-46.9).
- Substantial heterogeneity was observed across studies, with I² values of 99.49% for osteoporosis and 95.85% for low bone mass.
- No statistically significant links were found between ADT duration and overall prevalence.
Why it matters
Understanding the prevalence of osteoporosis and low bone mass in men with prostate cancer is crucial for developing effective management strategies. This knowledge can guide clinicians in monitoring and addressing bone health in this patient population.
What to keep in mind
The review's findings are limited by substantial heterogeneity across studies and the lack of data on fracture incidence, screening effectiveness, or treatment efficacy.